Indian pharma major Cipla said that it is open to the possibility of marketing Eli Lilly’s weight loss drugs in India.
“We currently have a very nice working relation with Eli Lilly for the insulin range. So we are always open” Umang Vohra, CEO, Cipla.
Currently, Eli Lilly has a strategic partnership in India with Cipla to enhance the reach of Eli Lilly’s Diabetes products – Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide) from 2021.
As a part of this agreement, Lilly had transfered its rights in India to sell, promote and distribute the two Lilly Diabetes products to Cipla.
In February, Eli Lilly CEO David Ricks said that the company expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year (2025) after it clears an ongoing regulatory review.
Mounjaro (tirzepatide) injection, is a prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
The management expects EBITDA margins to come at 25 percent for FY 25. EBITDA for FY24 came in at Rs 6233 crore and 24.5 percent EBITDA margin in the period.
The company is also closer to the remediation of its plant in Indore for the US FDA inspection. The plant has been under scrutiny for some time due to regulatory lapses. Analysts at Jefferies had estimated that the Indore plant contributes around 30 percent to Cipla's US sales and 8 percent to overall sales in a November 26 report.
Pharma major Cipla has reported a consolidated net profit of Rs 939 crore for the January to March period, up 79 percent year-on-year (YoY), compared with Rs 525.6 crore in the year-ago period.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
